The Biology of the HIV-1 Latent Reservoir and Implicati

Cell Host and Microbe
27, 519-530
DOI: 10.1016/j.chom.2020.03.014

Citation Report

#	Article	IF	Citations
1	Immunological approaches to HIV cure. Seminars in Immunology, 2021, 51, 101412.	2.7	39
2	Immune Checkpoints in Viral Infections. Viruses, 2020, 12, 1051.	1.5	33
3	Advances in Continuous Microfluidics-Based Technologies for the Study of HIV Infection. Viruses, 2020, 12, 982.	1.5	9
4	Experimental Systems for Measuring HIV Latency and Reactivation. Viruses, 2020, 12, 1279.	1.5	15
5	HIV-1 Proviral Transcription and Latency in the New Era. Viruses, 2020, 12, 555.	1.5	29
6	Unconventional CD45RA+ memory CD8 T cells to control HIV infection during antiretroviral therapy. Cellular and Molecular Immunology, 2020, 17, 897-898.	4.8	2
7	Bringing Gene Therapies for HIV Disease to Resource-Limited Parts of the World. Human Gene Therapy, 2021, 32, 21-30.	1.4	8
8	Chronic obstructive pulmonary disease in HIV. Expert Review of Respiratory Medicine, 2021, 15, 71-87.	1.0	17
9	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 225-233.	1.9	80
10	HIV-1 Entry and Prospects for Protecting against Infection. Microorganisms, 2021, 9, 228.	1.6	5
11	Shocking HIV-1 with immunomodulatory latency reversing agents. Seminars in Immunology, 2021, 51, 101478.	2.7	11
12	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight, 2021, 6, .	2.3	40
13	Antigen-driven clonal selection shapes the persistence of HIV-1â€“infected CD4+ T cells in vivo. Journal of Clinical Investigation, 2021, 131, .	3.9	103
15	Antivirals with common targets against highly pathogenic viruses. Cell, 2021, 184, 1604-1620.	13.5	78
16	Chimeric antigen receptor T-cell therapy for HIV cure. Current Opinion in HIV and AIDS, 2021, 16, 88-97.	1.5	6
17	Improved Detection of HIV Gag p24 Protein Using a Combined Immunoprecipitation and Digital ELISA Method. Frontiers in Microbiology, 2021, 12, 636703.	1.5	12
18	In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?. Viruses, 2021, 13, 501.	1.5	16
19	Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy. Journal of Clinical Investigation, 2021, 131, .	3.9	11

#	Article	IF	Citations
20	Gut Microbiome Homeostasis and the CD4 T- Follicular Helper Cell IgA Axis in Human Immunodeficiency Virus Infection. Frontiers in Immunology, 2021, 12, 657679.	2.2	6
21	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine, 2021, 65, 103270.	2.7	46
22	Unified model of short- and long-term HIV viral rebound for clinical trial planning. Journal of the Royal Society Interface, 2021, 18, 20201015.	1.5	6
23	Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. PLoS Pathogens, 2021, 17, e1009141.	2.1	36
24	The Architecture of Circulating Immune Cells Is Dysregulated in People Living With HIV on Long Term Antiretroviral Treatment and Relates With Markers of the HIV-1 Reservoir, Cytomegalovirus, and Microbial Translocation. Frontiers in Immunology, 2021, 12, 661990.	2.2	19
25	Mechanisms of residual immune activation in HIV-1-infected human lymphoid tissue ex vivo. Aids, 2021, 35, 1179-1190.	1.0	2
26	Visualization of HIV-1 reservoir: an imaging perspective. Current Opinion in HIV and AIDS, 2021, 16, 232-239.	1.5	1
27	CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues. Frontiers in Immunology, 2021, 12, 695148.	2.2	8
28	Overt IL-32 isoform expression at intestinal level during HIV-1 infection is negatively regulated by IL-17A. Aids, 2021, 35, 1881-1894.	1.0	4
29	Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure. Frontiers in Immunology, 2021, 12, 708806.	2.2	11
30	Transient CD4-cell-depletion therapy for HIV/AIDS cure. Chinese Medical Journal, 2021, 134, 1930-1932.	0.9	1
31	Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations. Current HIV/AIDS Reports, 2021, 18, 475-482.	1.1	3
32	Viral, inflammatory, and reservoir characteristics of posttreatment controllers. Current Opinion in HIV and AIDS, 2021, 16, 249-256.	1.5	3
33	Low-Level Anorectal HIV Shedding despite Effective Antiretroviral Therapy Is Not Driven by Mucosal Inflammation. Journal of Immunology, 2021, 207, 685-695.	0.4	0
34	HIV and Messenger RNA Vaccine. Cureus, 2021, 13, e16197.	0.2	9
35	Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection. Nature Communications, 2021, 12, 5143.	5.8	7
36	Clonal Hematopoiesis Is Associated With Low CD4 Nadir and Increased Residual HIV Transcriptional Activity in Virally Suppressed Individuals With HIV. Journal of Infectious Diseases, 2022, 225, 1339-1347.	1.9	17
37	A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. Frontiers in Immunology, 2021, 12, 726419.	2.2	28

#	Article	IF	Citations
38	The Current Status of Latency Reversing Agents for HIV-1 Remission. Annual Review of Virology, 2021, 8, 491-514.	3.0	44
39	MAT2A-Mediated S-Adenosylmethionine Level in CD4+ T Cells Regulates HIV-1 Latent Infection. Frontiers in Immunology, 2021, 12, 745784.	2.2	3
40	Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Microbiology Spectrum, 2021, 9, e0070821.	1.2	38
41	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	2.1	25
42	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 224, 92-100.	1.9	57
43	Editing of the TRIM5 Gene Decreases the Permissiveness of Human T Lymphocytic Cells to HIV-1. Viruses, 2021, 13, 24.	1.5	6
44	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. ELife, 2020, 9, .	2.8	63
45	Hallmarks of Retroelement Expression in T-Cells Treated With HDAC Inhibitors. Frontiers in Virology, 2021, 1, .	0.7	5
46	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. Journal of Experimental Medicine, 2021, 218, .	4.2	32
47	IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ TÂcells. IScience, 2021, 24, 103225.	1.9	3
57	Hydrogen sulfide blocks HIV rebound by maintaining mitochondrial bioenergetics and redox homeostasis. ELife, 2021, 10, .	2.8	4
58	Are HIV-1-Specific Antibody Levels Potentially Useful Laboratory Markers to Estimate HIV Reservoir Size? A Review. Frontiers in Immunology, 2021, 12, 786341.	2.2	2
59	Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. EClinicalMedicine, 2021, 42, 101225.	3.2	5
60	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. MBio, 2022, 13, e0338421.	1.8	4
61	4â€²-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives. Accounts of Chemical Research, 2022, 55, 565-578.	7.6	30
62	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	52
63	Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda. Retrovirology, 2022, 19, 1.	0.9	5
64	Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary. Molecules, 2022, 27, 850.	1.7	15

#	Article	IF	Citations
65	Immune checkpoint blockade in HIV. EBioMedicine, 2022, 76, 103840.	2.7	15
66	HIV-Sheltering Platelets From Immunological Non-Responders Induce a Dysfunctional Glycolytic CD4+ T-Cell Profile. Frontiers in Immunology, 2021, 12, 781923.	2.2	1
67	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. Toxins, 2022, 14, 138.	1.5	6
69	HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers. Biomedicines, 2022, 10, 768.	1.4	4
70	Host Restriction Factors Modulating HIV Latency and Replication in Macrophages. International Journal of Molecular Sciences, 2022, 23, 3021.	1.8	9
71	HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies. Current HIV/AIDS Reports, 2022, 19, 194-206.	1.1	10
72	Peripheral blood CD4+CCR6+ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals. Communications Biology, 2022, 5, 357.	2.0	2
73	Single-Cell Profiling of Latently SIV-Infected CD4 ⁺ T Cells Directly Ex Vivo to Reveal Host Factors Supporting Reservoir Persistence. Microbiology Spectrum, 2022, 10, e0060422.	1.2	1
74	Navigating the complexity of chronic HIV-1 associated immune dysregulation. Current Opinion in Immunology, 2022, 76, 102186.	2.4	7
75	HIV Latency in Myeloid Cells: Challenges for a Cure. Pathogens, 2022, 11, 611.	1.2	11
76	CBX4 contributes to HIVâ€1 latency by forming phaseâ€separated nuclear bodies and SUMOylating EZH2. EMBO Reports, 2022, 23, .	2.0	12
77	Combination anti-HIV antibodies provide sustained virological suppression. Nature, 2022, 606, 375-381.	13.7	65
78	Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV. EBioMedicine, 2022, 81, 104090.	2.7	11
80	HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine. Expert Review of Vaccines, 0, , 1-11.	2.0	1
81	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. Nature Communications, 2022, 13, .	5.8	12
83	Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV. BioTech, 2022, 11, 25.	1.3	5
84	Off-Target Effect of Activation of NF-ÎºB by HIV Latency Reversal Agents on Transposable Elements Expression. Viruses, 2022, 14, 1571.	1.5	3
85	Lenalidomide potentially reduced the level of cell- associated HIV RNA and improved persistent inflammation in patients with HIV-associated cryptococcal meningitis a pilot study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	1

#	Article	IF	Citations
86	Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. Frontiers in Immunology, 0, 13, .	2.2	10
87	The reservoir of latent HIV. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	16
88	Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth. Nature Communications, 2022, 13, .	5.8	1
89	Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies. Scientific Reports, 2022, 12, .	1.6	0
90	Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation. Pathogens, 2022, 11, 891.	1.2	1
91	In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV. Scientific Reports, 2022, 12, .	1.6	3
92	Functional cure of a chronic virus infection by shifting the virus - host equilibrium state. Frontiers in Immunology, 0, 13, .	2.2	3
93	Distinct gene expression by expanded clones of quiescent memory CD4+ TÂcells harboring intact latent HIV-1 proviruses. Cell Reports, 2022, 40, 111311.	2.9	18
94	Chimeric antigen receptor engineered cells and their clinical application in infectious disease. Clinical and Translational Discovery, 2022, 2, .	0.2	0
95	Tuning Rex rules HTLV-1 pathogenesis. Frontiers in Immunology, 0, 13, .	2.2	3
96	Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells. Clinical Microbiology Reviews, 2022, 35, .	5.7	8
98	Duration of antiretroviral therapy impacts the degree of residual SIV infection in the gut in longâ€term nonâ€progressing Chinese rhesus macaques. Journal of Medical Virology, 2023, 95, .	2.5	0
99	Systematic post-mortem analysis of brain tissue from an HIV-1 subtype C viremic decedent revealed a paucity of infection and pathology. Journal of NeuroVirology, 2022, 28, 527-536.	1.0	2
100	S100A8-mediated metabolic adaptation controls HIV-1 persistence in macrophages in vivo. Nature Communications, 2022, 13, .	5.8	10
101	Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection. MBio, 2022, 13, .	1.8	1
103	HIV specific CD8+ TRM-like cells in tonsils express exhaustive signatures in the absence of natural HIV control. Frontiers in Immunology, 0, 13, .	2.2	3
104	FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation. Emerging Microbes and Infections, 2022, 11, 2785-2799.	3.0	2
105	Host Molecule Incorporation into HIV Virions, Potential Influences in HIV Pathogenesis. Viruses, 2022, 14, 2523.	1.5	1

#	Article	IF	Citations
106	Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine. Drug Metabolism and Disposition, 2023, 51, 360-368.	1.7	3
107	HIV cure: an acceptability scientific agenda. Current Opinion in HIV and AIDS, 2023, 18, 12-17.	1.5	2
109	Elevated inflammatory fecal immune factors in men who have sex with men with HIV associate with microbiome composition and gut barrier function. Frontiers in Immunology, 0, 13, .	2.2	6
111	Medicinal chemistry insights into antiviral peptidomimetics. Drug Discovery Today, 2023, 28, 103468.	3.2	9
112	Genome-wide associated variants of subclinical atherosclerosis among young people with HIV and gene-environment interactions. Journal of Translational Medicine, 2022, 20, .	1.8	2
113	Inhibition of the TRIM24 bromodomain reactivates latent HIV-1. Scientific Reports, 2023, 13, .	1.6	9
114	TRIM24 controls induction of latent HIV-1 by stimulating transcriptional elongation. Communications Biology, 2023, 6, .	2.0	8
115	Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4. Frontiers in Immunology, 0, 14, .	2.2	5
116	Recent Advances in PROTAC-Based Antiviral Strategies. Vaccines, 2023, 11, 270.	2.1	13
117	Virally Suppressed People Living with HIV Who Use Opioids Have Diminished Latency Reversal. Viruses, 2023, 15, 415.	1.5	4
118	HIV persistence: silence or resistance?. Current Opinion in Virology, 2023, 59, 101301.	2.6	10
119	Tracing the recent updates on vaccination approaches and significant adjuvants being developed against HIV. Expert Review of Anti-Infective Therapy, 2023, 21, 431-446.	2.0	0
121	Transforming Growth Factor Î² Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4 ⁺ T Cells. Journal of Virology, 2023, 97, .	1.5	4
144	Molecular mechanisms by which the HIV-1 latent reservoir is established and therapeutic strategies for its elimination. Archives of Virology, 2023, 168, .	0.9	0